Perrigo Company plc Ordinary Shares (PRGO)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses whose earnings I can predict and whose price offers a margin of safety. Perrigo is a recognizable consumer self-care company, with over-the-counter products and about $4.3B of revenue in fiscal year 2025, the year ended 2025-12-31. But the record is not that of a steady compounder. In fiscal year 2023, ended 2023-12-31, it reported a net loss of $12.7M; in fiscal year 2024, ended 2024-12-31, a net loss of $171.8M; and in fiscal year 2025, ended 2025-12-31, a net loss of $1.4B. Revenue also slipped from $4.7B in fiscal year 2023 to $4.4B in fiscal year 2024 and $4.3B in fiscal year 2025. The latest fiscal Q2 2026, the quarter ended 2026-06-27, was better: revenue of $1.0B, net income of $74.5M, and diluted EPS of $0.53. Yet fiscal Q1 2026, the quarter ended 2026-03-28, had a $398.6M net loss, so consistency is missing. At the 2026-10-13 close of $15.37, FairStock calculations show a market cap of $2.1B, a negative P/E of -1.25, and P/B of 0.85. The asset value looks cheap, but book value may be impaired, and Altman Z of -0.11 and D/E of 1.38 signal financial risk. TTM free cash flow is $119.3M, a 5.6% FCF yield, while the 8.55% dividend yield looks demanding. Piotroski F-Score of 6/9 is middling. The consumer OTC business has scale and retail relationships, but pricing power is limited. Until profits and revenue stabilize, this is a speculation on a turnaround, not a clear value bargain.

In plain English: Perrigo sells over-the-counter health and wellness products, such as cough, allergy, digestive, and nutrition items, mainly under store-brand or retail labels. The business has been weak: it lost money in each of the last several years, although the latest quarter showed a small profit and it still generates cash. The stock price looks low compared with the company's stated book value, but the losses and heavy debt mean it is not clearly a bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-27) · fiscal Q1 2026 10-Q (period ended 2026-03-28) · fiscal Q3 2025 10-Q (period ended 2025-09-27) · fiscal Q2 2025 10-Q (period ended 2025-06-28) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer